Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Site-Targeted Drug Delivery Systems: Polymeric Carriers01:24

Site-Targeted Drug Delivery Systems: Polymeric Carriers

Polymeric carriers enhance targeted drug delivery by increasing efficacy while minimizing off-target effects. These carriers comprise a biodegradable polymeric backbone integrated with functional elements that enable targeting, improve physicochemical properties, and regulate drug release.Targeting MechanismsThe targeting ability of polymeric carriers is mediated by a homing device, which is a molecular recognition component designed to selectively bind to specific tissues or cells. Monoclonal...
Modified-Release Drug Delivery Systems: Site-Targeted01:24

Modified-Release Drug Delivery Systems: Site-Targeted

Site-targeted drug delivery systems enhance therapeutic efficacy while minimizing systemic toxicity and treatment costs. Unlike conventional methods, these systems ensure precise drug delivery, improving bioavailability and reducing side effects. Targeted drug delivery is classified into three levels. First-order targeting directs drugs to the capillary beds of specific organs or tissues. Second-order targets specific cell types, such as tumor cells, using receptor-mediated interactions.
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention01:05

Bioavailability Enhancement: Drug Stability Enhancement and GI Retention

Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
Oral Drug Delivery Systems: Delayed-Release Systems01:11

Oral Drug Delivery Systems: Delayed-Release Systems

Delayed-release drug delivery systems are specialized pharmaceutical formulations designed to postpone the release of active compounds until the drug reaches a specific region of the gastrointestinal (GI) tract, typically the intestine. These systems are essential for drugs that may cause gastric irritation, are unstable in acidic environments, or need to exert therapeutic effects locally in the intestinal or colonic regions.The core feature of delayed-release systems is the use of enteric...
Drug Delivery Systems: Different Types01:27

Drug Delivery Systems: Different Types

Conventional oral drug products, termed immediate-release (IR) formulations, are engineered to promptly release their active pharmaceutical ingredient (API) upon ingestion, typically in tablets or capsules. This rapid release often results in swift drug absorption and consequent pharmacodynamic effects, although the timing and intensity can vary depending on the drug's properties. Prodrugs within these formulations require metabolic conversion to activate their pharmacodynamic effects,...
Modified-Release Drug Delivery Systems: Rate-Programmed II01:19

Modified-Release Drug Delivery Systems: Rate-Programmed II

Rate-programmed drug delivery systems release drugs in a controlled manner to maintain therapeutic levels. Three main designs include reservoir, matrix, and hybrid systems.Reservoir systems consist of a drug core enclosed within a membrane that controls drug release. In non-swelling reservoir systems, polymers like ethyl cellulose or polymethacrylates are used. These do not hydrate in aqueous media and control release through membrane thickness, porosity, or insolubility. This type includes...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rheological Characterization of Lemon Oil-Loaded Eucerin Cream and Aquaphor Ointment.

Pharmaceuticals (Basel, Switzerland)·2025
Same author

2025 Top JPharmSci Reviewers.

Journal of pharmaceutical sciences·2025
Same author

MDM2 and DNMT1 inhibitors induce neuroblastoma cell death through p53-dependent and independent pathways.

Epigenomics·2025
Same author

Regulation of PD-L1 Expression by SAHA-Mediated Histone Deacetylase Inhibition in Lung Cancer Cells.

Cancers·2025
Same author

Editorial: Hypoxia and angiogenesis in cancer.

Frontiers in pharmacology·2024
Same author

Enhancement of MDM2 inhibitory effects through blocking nuclear export mechanisms in ovarian cancer cells.

Cancer genetics·2022

Related Experiment Video

Updated: Jul 19, 2026

Porous Silicon Microparticles for Delivery of siRNA Therapeutics
08:31

Porous Silicon Microparticles for Delivery of siRNA Therapeutics

Published on: January 15, 2015

SiRNA drug delivery by biodegradable polymeric nanoparticles.

Xudong Yuan1, Ling Li, Appu Rathinavelu

  • 1Division of Pharmaceutical Sciences, Arnold and Marie Schwartz College of Pharmacy and Health Sciences, Long Island University, 75 Dekalb Avenue, NY 11201, USA.

Journal of Nanoscience and Nanotechnology
|October 20, 2006
PubMed
Summary

Biodegradable nanoparticles effectively deliver small interfering RNA (siRNA) for gene silencing. This novel drug delivery system shows promise for future clinical applications in siRNA therapeutics.

More Related Videos

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery
09:09

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery

Published on: May 2, 2019

Manufacture and Drug Delivery Applications of Silk Nanoparticles
09:03

Manufacture and Drug Delivery Applications of Silk Nanoparticles

Published on: October 8, 2016

Related Experiment Videos

Last Updated: Jul 19, 2026

Porous Silicon Microparticles for Delivery of siRNA Therapeutics
08:31

Porous Silicon Microparticles for Delivery of siRNA Therapeutics

Published on: January 15, 2015

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery
09:09

Preparation of Neutrally-charged, pH-responsive Polymeric Nanoparticles for Cytosolic siRNA Delivery

Published on: May 2, 2019

Manufacture and Drug Delivery Applications of Silk Nanoparticles
09:03

Manufacture and Drug Delivery Applications of Silk Nanoparticles

Published on: October 8, 2016

Area of Science:

  • Biotechnology
  • Nanomedicine
  • Molecular Biology

Background:

  • RNA interference (RNAi) utilizes double-stranded RNA (dsRNA) to degrade complementary mRNA.
  • Small interfering RNA (siRNA) shows therapeutic potential, but effective drug delivery remains a challenge.
  • Biodegradable polymers offer a promising platform for novel drug delivery systems.

Purpose of the Study:

  • To develop and characterize a biodegradable poly(D,L-lactide-co-glycolide) (PLGA) nanoparticle system for siRNA delivery.
  • To evaluate the efficiency of siRNA loading and cellular uptake of the PLGA nanoparticles.
  • To assess the gene silencing efficacy of siRNA delivered via PLGA nanoparticles.

Main Methods:

  • Preparation and characterization of PLGA nanoparticles using scanning electron microscopy and laser diffraction.
  • Delivery of fluorescently labeled siRNA (Cy3-oligos) into 293T cells.
  • Assessment of gene silencing using fluorescent microscopy to observe GFP expression inhibition by si-GFP-RNA loaded nanoparticles.

Main Results:

  • PLGA nanoparticles were successfully prepared with desired physicochemical properties.
  • Effective delivery and cellular uptake of siRNA into targeted 293T cells were confirmed.
  • Significant GFP gene silencing was observed, demonstrating the efficacy of the siRNA-loaded nanoparticles.

Conclusions:

  • Biodegradable PLGA nanoparticles provide an effective system for siRNA drug delivery.
  • This nanoparticle system demonstrates prominent gene silencing capabilities.
  • The improved formulation stability offers practical benefits for potential clinical translation of siRNA therapeutics.